Astrazeneca Plc Stock Current Valuation
ZEG Stock | 124.55 0.05 0.04% |
Valuation analysis of AstraZeneca PLC helps investors to measure AstraZeneca PLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
AstraZeneca PLC's intrinsic value may or may not be the same as its current market price of 124.55, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 124.55 | Real 113.34 | Hype 124.55 |
The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Company Current Valuation Analysis
AstraZeneca PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AstraZeneca PLC Current Valuation | 228.75 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, AstraZeneca PLC has a Current Valuation of 228.75 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-General industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
AstraZeneca Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is rated third in current valuation category among its peers.
AstraZeneca Fundamentals
Return On Equity | 0.0863 | |||
Return On Asset | 0.0555 | |||
Profit Margin | 0.07 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 228.75 B | |||
Shares Outstanding | 1.55 B | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 47.60 % | |||
Price To Book | 6.14 X | |||
Price To Sales | 4.41 X | |||
Revenue | 44.35 B | |||
Gross Profit | 35.73 B | |||
EBITDA | 9.33 B | |||
Net Income | 2.5 B | |||
Total Debt | 22.96 B | |||
Book Value Per Share | 23.90 X | |||
Cash Flow From Operations | 9.81 B | |||
Earnings Per Share | 2.00 X | |||
Price To Earnings To Growth | 1.36 X | |||
Number Of Employees | 83.5 K | |||
Beta | 0.19 | |||
Market Capitalization | 194.87 B | |||
Total Asset | 96.48 B | |||
Z Score | 4.8 | |||
Annual Yield | 0.02 % | |||
Net Asset | 96.48 B | |||
Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.